Abstract: A delivery vehicle, for delivering a pharmaceutically active agent or a marker to a cell, comprising a ligand binding portion specific for a Fas Ligand, and a carrier for the pharmaceutically active agent or marker.

Abstract: The present invention provides a specific binding molecule that binds to Annexin-1 (Anx-A1) for use in the treatment of obsessive compulsive disorder (OCD) or a disease related to OCD. The invention also provides a pharmaceutical composition comprising a specific binding molecule of the invention for use in the treatment of obsessive compulsive disorder (OCD) or a disease related to OCD.

Abstract: Gene expression data provides a basis for more accurate identification and diagnosis of lymphoproliferative disorders. In addition, gene expression data can be used to develop more accurate predictors of survival. The present invention discloses methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention discloses a novel microarray, the Lymph Dx microarray, for obtaining gene expression data from a lymphoma sample. The invention also discloses a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma. This information will be useful in developing the therapeutic approach to be used with a particular subject.

Abstract: An electrospray emitter (10) for emitting a liquid comprising a sheet (40) having a channel (65) opening to an aperture (55) on a flat emitter surface extending across the sheet (40). A charging electrode (80) coupleable to an electrical supply and arranged to apply an electrical charge to liquid passing into the channel (65). A control electrode (50) proximal to the channel (65) for controlling electrospray emission, that may be embedded in the sheet. A non-wetting or insulating layer (30) may be applied to the sheet.

Abstract: The present invention provides a method of quantifying the activity of a protein modifying enzyme in a sample, comprising: (i) grouping modified peptides from a first sample and modified peptides from a second sample into a single group according to one of the following parameters: (a) modified peptides having a modification site that is modified by the same protein modifying enzyme; or (b) modified peptides having a modification site that is part of the same modification motif; (ii) calculating enrichment of the modified peptides from the first sample compared to the modified peptides from the second sample in the group; and (iii) calculating the statistical significance of said enrichment; wherein a statistically significant enrichment is indicative of a protein modifying enzyme being activated in the first sample compared to the second sample. In some embodiments, the method further comprises identifying modified peptides in a first sample and a second sample using mass spectrometry (MS) prior to step (i).

Abstract: Gene expression data provides a basis for more accurate identification and diagnosis of lymphoproliferative disorders. In addition, gene expression data can be used to develop more accurate predictors of survival. The present invention discloses methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention discloses a novel microarray, the Lymph Dx microarray, for obtaining gene expression data from a lymphoma sample. The invention also discloses a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma. This information will be useful in developing the therapeutic approach to be used with a particular subject.

Abstract: A leucite glass-ceramic is prepared from a glass comprising: about 66.8 to about 71.9 mol % of SiO2, about 8.5 to about 10.6 mol % of Al2O3, about 9.5 to about 12.8 mol % of K2O, about 0.5 to about 4.0 mol % of CaO, about 0 to about 3.0 mol % of TiO2, about 1.8 to about 4.0 mol % of Na2O, about 0.1 to about 6.0 mol % of Li2O, about 0 to about 1.0 mol % of MgO, about 0 to about 3.0 mol % of Nb2O5, and about 0 to about 3.0 mol % of B2O3. The leucite glass-ceramic is prepared by subjecting the glass components to a nucleation heat treatment, followed by a growth heat treatment. The leucite glass-ceramic may be used in the fabrication of a Dental restoration using various processes, and may be used in the construction of Dental restorations such as ceramic Dental inlays, crowns, veneers, bridges, veneering materials for zirconium oxide restoration substrates, alumina oxide restoration substrates, or metal restoration substrates.

Abstract: The present invention provides a composition comprising an antibody or fragment thereof against oxidized Collagen II (CII) in which the antibody or fragment thereof is conjugated to a pharmaceutically active moiety. The invention also provides a composition comprising an antibody or fragment thereof against oxidized Collagen II (Gil) and a detectable label. The invention further provides the use of such compositions in medicine, in particular for the treatment of an arthropathy, and in methods of diagnosis.

Abstract: An optoelectronic signal translating device having a region containing rare earth or transition metal ions for generation of radiation of a predetermined wavelength. Said region includes an organic complex comprising a ligand adapted to enhance the emission of radiation and a chromophore separately co-operable with a radiation source of wavelength not greater than that of said predetermined desired radiation. Said chromophore can be excited to cross-couple with the upper permitted energy state of said rare earth or transition metal ions, thereby generating said predetermined desired radiation by subsequent decay of said ions to the permitted lower energy state.

Abstract: The present invention relates compounds according to Formula (I) wherein R1 and R2 are independently H or an optionally substituted group selected from an alkyl, a heteroalkyl, an aryl, a heteroaryl, an arylalkyl, and a heteroarylalkyl, and R3 and R4 taken together form a carbonyl (?O); or wherein R1 and R2 are independently H or an optionally substituted group selected from an alkyl, a heteroalkyl, an aryl, a heteroaryl, an arylalkyl, and a heteroarylalkyl, R3 is H and R4 is H or —OR5, wherein R5 is H or an optionally substituted group selected from an alkyl, a heteroalkyl, an aryl, a heteroaryl, an arylalkyl, and a heteroarylalkyl; or pharmaceutically acceptable salts or esters thereof, for use in the treatment of kidney disease, in particular in the treatment of acute kidney injury. The present invention also relates to methods of treatment of the same and methods of kidney transplant surgery and coronary artery bypass graft surgery using the compounds of Formula (I).

Abstract: The present invention relates to a stable protein and/or amino acid detecting composition that can be used as a reagent for in situ detection, such as on surfaces. The invention also relates to a method for detecting protein and/or amino acid on surfaces using the composition and kits comprising the composition.

Abstract: The present invention relates to a stapler apparatus, comprising a stapler having a proximal end, a distal end and a longitudinal axis, the stapler further comprising a trigger, an anvil docking pin aligned substantially parallel with the longitudinal axis of the stapler, and a stapling means, the anvil docking pin and stapling means being at the distal end of the stapler, and a detachable anvil, comprising an anvil head and an anvil shaft, wherein the anvil shaft is adapted to receive the anvil docking pin and operation of the trigger causes the stapling means to be actuated, characterised in that the length of the anvil shaft is at least 4 cm. The present invention also relates to a method of forming an anastomosis between two surfaces using the stapler apparatus of the invention and a method of forming a stoma trephine in a subject using the stapler apparatus of the invention.

Abstract: The present invention provides a specific binding molecule which specifically binds to a peptide having the amino acid sequence of EDGIKRIQDD and comprises a polypeptide having an immunoglobulin VL domain linked to an immunoglobulin VH domain in which the VL domain comprises Complementarity Determining Regions (CDRs) VLCDR1, VLCDR2 and VLCDR3, and in which the VH domain comprises Complementarity Determining Regions (CDRs) VHCDR1, VHCDR2, VHCDR3, each having a respective amino acid sequence as follows in which VHCDR1 is GYSFTGYNMN VHCDR2 is NIDPYYGGTTYNQKFKG VHCDR3 is EVDY VLCDR1 is RASKSVSTSTSGYSYMH VLCDR2 is LVSNLES VLCDR3 is QHIRELTRSEG or an amino acid sequence at least 70% identical thereto.

Abstract: The present invention provides an antigen binding polypeptide which specifically targets the synovial microvasculature of arthritis patients and comprises one or more complementarity determining regions (CDRs) selected from the group consisting of SEQ ID NOs 1 to 4. The present invention also relates to the use of such antigen binding polypeptides and conjugates thereof for use in the diagnosis and treatment of arthritis.

Abstract: An optoelectronic signal translating device having a region containing rare earth or transition metal ions for generation of radiation of a predetermined wavelength. Said region includes an organic complex comprising a ligand adapted to enhance the emission of radiation and a chromophore separately co-operable with a radiation source of wavelength not greater than that of said predetermined desired radiation. Said chromophore can be excited to cross-couple with the upper permitted energy state of said rare earth or transition metal ions, thereby generating said predetermined desired radiation by subsequent decay of said ions to the permitted lower energy state.

Abstract: An electrostatic spraying device (1) and method for dispensing a controlled volume of liquid in pulses using an emitter (2) having a spray area (29) from which the liquid can be sprayed, a means for injecting charges into the liquid, whereby, in use, the liquid (3) is delivered to the spray area by electrostatic forces and electrostatic spraying occurs in one or more pulses whilst the charges are injected. The charges may be injected by a time-varying or constant non-zero electric field so that electrospray occurs above a threshold value.

Abstract: A composition for making a cement or an implant, the composition comprising a silicate glass and at least one compound selected from the group consisting of a calcium phosphate salt, a strontium phosphate salt and a phosphate glass.

Abstract: A bioactive glass composition comprising one or more glasses comprising Si02, P205 and a fluoride, the Si02 content being less than 40 mole %, the P205 content being at least 4 mole %, and the fluoride content being greater than 1 mole %. The bioactive glass or glass-ceramic can be used in a number of medical applications, including dental applications such as toothpaste.

Abstract: The present invention relates to the treatment of trauma haemorrhage or trauma haemorrhage-induced organ injury and associated disorders (in particular stoke, burns and brain injury) using the anti-malarial compound artemisinin and its derivatives. The present invention also relates to the treatment of myocardial infarction and coronary heart disease (and associated disorders) using the anti-malarial compound artemisinin and its derivatives. The present invention also relates to the use of artemisinin and its derivatives in coronary artery bypass surgery, heart transplantation, and diseases associated with ischaemia-reperfusion.

Abstract: The present invention provides a specific binding molecule raised against the human Anx-A1 protein having the amino acid sequence shown in FIG. 2A. The present invention also relates to the sue of such a specific binding molecule in the treatment of T cell-mediated disease.